China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news
China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy available in China...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news
Patient-Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard-of-Care Treatments
Multiple studies showed improved patient outcomes and increased quality of life (QOL) among various treatments that previously demonstrated clinical benefits. These patient-centric findings, along with a promising new combination therapy for patients with advanced hepatocellular carcinoma (HCC) highlight some of the latest research to come out of the 2020 Gastrointestinal Cancers Symposium, held January 23-25, in San Francisco, California. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news
Many Patients With NAFLD Should Be Screened for Liver Cancer, Experts Say Many Patients With NAFLD Should Be Screened for Liver Cancer, Experts Say
Screening and surveillance for hepatocellular carcinoma (HCC) is important in many patients with nonalcoholic fatty liver disease (NAFLD), according to an expert panel of the American Gastroenterological Association (AGA).Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 11, 2020 Category: Pathology Tags: Gastroenterology News Source Type: news
Roche to present new data on Tecentriq in combination with Avastin that shows improvement in overall survival for Chinese patients with the most common form of liver cancer
Basel, 7 February 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that additional data will be presented from a cohort of Chinese patients in the Phase III IMbrave150 study that evaluated Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Data from 194 Chinese patients who took part in the IMbrave150 study were consistent with the global results, that showed a statistically significant and clinically meaningful improvement in overall survival (OS) and progression-free survi...
Source: Roche Investor Update - February 7, 2020 Category: Pharmaceuticals Source Type: news
Nonalcoholic Liver Disease'an Epidemic of the 21st Century'Nonalcoholic Liver Disease'an Epidemic of the 21st Century '
Can trigger a cascade of reactions, leading to liver cirrhosis, hepatocellular carcinoma, and liver failure, explains an expert.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 5, 2020 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news
Liver Transplant for Hepatocellular Carcinoma in the U.S. Liver Transplant for Hepatocellular Carcinoma in the U.S.
How have the patterns and outcomes for HCC-related liver transplants evolved over the last thirty years? A new study examines the trends.American Journal of Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 3, 2020 Category: Surgery Tags: Transplantation Journal Article Source Type: news
Immunitor publishes interim results from Phase III trial of oral...
The Immunitor study is published in January issue of Hepatoma Research (ClinicalTrials.gov Identifier: NCT02232490).(PRWeb February 01, 2020)Read the full story at https://www.prweb.com/releases/immunitor_publishes_interim_results_from_phase_iii_trial_of_oral_immunotherapy_for_liver_cancer/prweb16874458.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 1, 2020 Category: Pharmaceuticals Source Type: news
QoL Extended With Atezolizumab & #43; Bevacizumab in Liver Cancer
WEDNESDAY, Jan. 29, 2020 -- For patients with unresectable hepatocellular carcinoma, the combination of atezolizumab and bevacizumab is associated with longer time to deterioration of patient-reported quality of life (QOL); and decline in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2020 Category: Pharmaceuticals Source Type: news
Effectiveness of DAA Treatment for HCV in Patients With HCC Effectiveness of DAA Treatment for HCV in Patients With HCC
Is virologic reponse to direct-acting antivirals as robust in HCV patients with hepatocellular carcinoma as in those without?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
New Therapeutic Interventions for Advanced HCC New Therapeutic Interventions for Advanced HCC
This article reviews the latest clinical trials on current and emerging first-line and second-line therapeutic options available for patients with advanced hepatocellular carcinoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 27, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
New Drug Combo Potentially Practice Changing in Advanced HCC New Drug Combo Potentially Practice Changing in Advanced HCC
Atezolizumab plus bevacizumab was superior to sorafenib for maintaining quality of life in patients with unresectable hepatocellular carcinoma (HCC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 27, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
Roche today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 27, 2020 Category: Pharmaceuticals Source Type: news
Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer
·Application is being reviewed under FDA ’s Real-Time Oncology Review pilot programmeBasel, 27 January 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the completion of a supplemental Biologics License Application (sBLA) submission to the US Food and Drug Administration (FDA) for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), for the treatment of people with unresectab le hepatocellular carcinoma (HCC) who have not received prior systemic therapy. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient...
Source: Roche Investor Update - January 27, 2020 Category: Pharmaceuticals Source Type: news
Genentech Submits sBLA for Atezolizumab Plus Bevacizumab Combo to Treat Unresectable HCC
The company ’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - January 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
